ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.102,15
0,75%
S&P 500
5.930,85
1,09%
US Dollar vs BRL
6,086
0,00%
Bitcoin
98.083,50
0,33%
Brent Oil
72,72
0,00%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Evolus Inc (EOLS)

  7. Evolus Inc (EOLS) Notícias

EOLS

Evolus (EOLS)

Evolus Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:EOLS
DataHoraFonteTítuloCódigoCompanhia
13/12/202418:05Business WireEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:EOLSEvolus Inc
06/11/202419:22Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:EOLSEvolus Inc
06/11/202418:37Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EOLSEvolus Inc
06/11/202418:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EOLSEvolus Inc
06/11/202418:05Business WireEvolus Reports Third Quarter 2024 ResultsNASDAQ:EOLSEvolus Inc
01/11/202409:00Business WireEvolus to Participate in Stifel 2024 Healthcare ConferenceNASDAQ:EOLSEvolus Inc
31/10/202415:02Business WireEvolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device RegulationNASDAQ:EOLSEvolus Inc
29/10/202409:00Business WireEvolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled ConsumersNASDAQ:EOLSEvolus Inc
23/10/202409:00Business WireEvolus to Report Third Quarter Financial Results on November 6, 2024NASDAQ:EOLSEvolus Inc
06/09/202422:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EOLSEvolus Inc
06/09/202409:00Business WireEvolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024NASDAQ:EOLSEvolus Inc
31/07/202417:05Business WireEvolus Reports Second Quarter 2024 Results and Raises Full Year Revenue GuidanceNASDAQ:EOLSEvolus Inc
31/07/202409:00Business WireEvolus to Hold Investor Day on September 12, 2024NASDAQ:EOLSEvolus Inc
30/07/202409:00Business WireEvolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in AustraliaNASDAQ:EOLSEvolus Inc
25/07/202409:00Business WireEvolus to Participate in the Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:EOLSEvolus Inc
17/07/202409:00Business WireEvolus to Report Second Quarter Financial Results on July 31, 2024NASDAQ:EOLSEvolus Inc
01/07/202409:00Business WireEvolus Announces Appointment of Albert G. White III to Board of DirectorsNASDAQ:EOLSEvolus Inc
24/06/202409:00Business WireEvolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler ProductsNASDAQ:EOLSEvolus Inc
12/06/202409:00Business WireEvolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in SpainNASDAQ:EOLSEvolus Inc
06/06/202418:45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:EOLSEvolus Inc
20/05/202409:30Business WireEvolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE MeetingNASDAQ:EOLSEvolus Inc
15/05/202409:30Business WireEvolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO SummitNASDAQ:EOLSEvolus Inc
10/05/202410:10Business WireEvolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the YearNASDAQ:EOLSEvolus Inc
07/05/202417:05Business WireEvolus Reports First Quarter 2024 Results and Provides Business UpdateNASDAQ:EOLSEvolus Inc
23/04/202417:30Business WireEvolus to Report First Quarter Financial Results on May 7, 2024NASDAQ:EOLSEvolus Inc
17/04/202417:05Business WireEvolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®NASDAQ:EOLSEvolus Inc
26/03/202409:00Business WireEvolus to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:EOLSEvolus Inc
11/03/202410:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EOLSEvolus Inc
11/03/202408:00Business WireEvolus Announces Pricing of $50.0 Million Underwritten Offering of Common StockNASDAQ:EOLSEvolus Inc
07/03/202418:42Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:EOLSEvolus Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:EOLS

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
FICT3
Fictor Alimentos
BOV
PRIO3
PETRORIO ON
BOV
AZEV4
AZEVEDO PN
BOV
TELB4
TELEBRAS PN
BOV
AMOB3
Automob Participacoes ON
BOV
ENGI11
ENERGISA
BOV
HBOR3
HELBOR ON
BOV
AZUL4
AZUL PN
BOV
INBR32
Inter &
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados